89bio, Inc. Profile Avatar - Palmy Investing

89bio, Inc.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibrob…

Biotechnology
US, San Francisco [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of ETNB's Analysis
CIK: 1785173 CUSIP: 282559103 ISIN: US2825591033 LEI: - UEI: -
Secondary Listings
ETNB has no secondary listings inside our databases.